rs115696360 - LINC02151
Magnitude 2.2 · 1 study on file
Reported associations
-
Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia. - Atherosclerosis (2022) · Trinder M, Vikulova D, Pimstone S, Mancini GBJ, Brunham LR · PubMed 34906840
Familial combined hyperlipidemia (FCHL) is one of the most common inherited lipid phenotypes, characterized by elevated plasma concentrations of apolipoprotein B-100 and triglycerides. The genetic inheritance of FCHL remains poorly understood. The goals of this study were to investigate the polygenetic architecture and cardiovascular risk associated with FCHL. We identified individuals with an FCHL phenotype among 349,222 unrelated participants of European ancestry in the UK Biobank using modified versions of 5 different diagnostic criteria. The prevalence of the FCHL phenotype was 11.44% (n = 39,961), 5.01% (n = 17,485), 1.48% (n = 5,153), 1.10% (n = 3,838), and 0.48% (n = 1,688) according to modified versions of the Consensus Conference, Dutch, Mexico, Brunzell, and Goldstein c
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Familial combined hyperlipidemia risk and management High
Genetic variant increases risk of familial combined hyperlipidemia; clinical assessment may guide dietary or pharmaceutical management
Discuss genetic risk, family history, and personalized management approach
Screening
-
Lipid panel for familial combined hyperlipidemia High
Genetic variant associated with familial combined hyperlipidemia, characterized by elevated cholesterol and/or triglycerides
Annual lipid panel (total cholesterol, LDL, HDL, triglycerides); more frequent if abnormal